Sanofi (ENXTPA: SAN) reported earnings on March 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sanofi met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.
Margins shrank across the board.
Sanofi tallied revenue of $11.24 billion. The 11 analysts polled by S&P Capital IQ expected to see a top line of $11.26 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.57. The 12 earnings estimates compiled by S&P Capital IQ averaged $1.55 per share. Non-GAAP EPS of $1.57 for Q4 were 23% lower than the prior-year quarter's $2.03 per share. GAAP EPS of $0.41 for Q4 were 71% lower than the prior-year quarter's $1.40 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.1%, 690 basis points worse than the prior-year quarter. Operating margin was 15.9%, much worse than the prior-year quarter. Net margin was 4.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $10.71 billion. On the bottom line, the average EPS estimate is $1.76.
Next year's average estimate for revenue is $46.32 billion. The average EPS estimate is $7.76.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $99.00.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Sanofi. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Sanofi to My Watchlist.